Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · NURECA

NURECA

HealthcareHealthcare Equipment & Supplies₹282 cr market cap
₹299.90 ▼ -0.81% today As of 19 Nov 2026
52-week low ₹206.7552-week high ₹366.60

-17.5% from the 52-week high · +46.2% above the low

Nureca Ltd. design and manufactures health monitoring devices. The company is headquartered in Mumbai, Maharashtra and currently employs 102 full-time employees. The company went IPO on 2021-02-25. The main products/services that the Company manufactures include chronic disease products, orthopedic products, mother and child products, nutrition supplements, lifestyle products, and connected devices. Its chronic disease products include nebulizers, BP monitors, finger pulse oximeters, glucose meters and thermometers. Its orthopedic products include wheelchairs, walkers, lumbar and tailbone supports and physiotherapy electric massagers. Its mother and babycare products include baby feeding, carry cots, baby skincare, nebulizers and bottle warmers and steamers. Its nutrition supplements include supplements and weight management products. Its lifestyle products include humidifiers and steamers, personal scales, massagers, fitness tracking, and dental and personal care. The firm's products are offered through its brands, such as Dr Trust, Dr Physio, and Trumom.

The short version. NURECA reported revenue of ₹59 crore for Sep 2026, up 55.3% from a year earlier. Net profit was ₹4 crore (up 0.0% year on year). Return on equity was 1.1% in Mar 2026. Promoter holding was 70.68% in Sep 2026, up 6.62 points over 8 quarters.

1 · The price

How has the stock traded?

NURECA trades 17.5% below its 52-week high and 46.2% above its 52-week low.

Change over period: —

1M-3.5%
3M-4.6%
6M+10.9%
1Y+13.7%

2 · The business

Is it growing?

Sales, year on year+55.3%

Sep 2026 revenue of ₹59 cr.

Profit, year on year+0.0%

Sep 2026 net profit of ₹4 cr.

Net margin6.9%

2.7 pts lower than a year earlier.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue5940354038343226
Net profit43-64412-3
Net margin %6.97.6-17.29.49.62.47.8-10.6
EPS (₹)4.253.22-6.383.733.630.812.47-2.8

Annual

FY2026FY2025FY2024FY2023FY2022FY2021
Revenue14711092111256213
Net profit21-2-84546
Net margin %1.40.8-2.0-7.417.621.7
EPS (₹)2.180.85-1.79-8.2544.9646.37

3 · The quality

How well does it turn capital into profit?

Return on equity was 1.1% in Mar 2026; debt to equity is 0.00.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %1.10.4-0.9-4.2
Return on capital %3.41.3-1.1-5.2
EBITDA margin %5.34.00.3-6.7
Net margin %1.30.7-1.8-7.0

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR9.4%-6.4%
Profit CAGR—-46.2%
Debt to equity0.00
Interest cover4.9x
Current ratio8.32
P/E ratio51.2

4 · The owners

Who holds it, and are they adding?

Promoter holding70.68%

Up 6.62 pts over 8 quarters.

Foreign institutions0.22%

Down 0.14 pts over 8 quarters.

Domestic institutions0.24%

Up 0.2 pts over 8 quarters.

Mutual fund schemes0

+0 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter64.0664.364.3364.9764.9768.0968.0970.68+6.62
FII0.361.070.070.070.080.280.110.22-0.14
DII0.040.040.040.040.040.240.240.24+0.2
Public35.5434.5935.5634.9234.9131.3931.5728.86-6.68

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for NURECA are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about NURECA

What is the NURECA share price?

NURECA (NURECA) last closed at ₹299.90, down 0.81% on the day. Its 52-week range is ₹206.75 to ₹366.60.

What is the market cap of NURECA?

NURECA has a market capitalisation of about ₹282 crore. Its price-to-earnings ratio is 51.2.

How are NURECA's latest results?

NURECA reported revenue of ₹59 crore for Sep 2026, up 55.3% from a year earlier. Net profit was ₹4 crore (up 0.0% year on year). Return on equity was 1.1% in Mar 2026. Promoter holding was 70.68% in Sep 2026, up 6.62 points over 8 quarters.

Who owns NURECA?

As of Sep 2026, shareholding was: Promoter 70.68%, FII 0.22%, DII 0.24%, Public 28.86%.

How many mutual funds hold NURECA?

0 mutual fund schemes held NURECA in October 2026. That compares with 0 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 24 Feb 2022 · Interim Dividend - Rs. 3
  • 21 Sep 2021 · Dividend - Rs. 2

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.